Bernhard Scheiner

机构：Medical University of Vienna · ORCID：0000-0002-4904-5133

发表论文 381 篇 · 总被引 8179 次 · h-index 47

代表论文

• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 11)
• Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease (2025 · Alimentary Pharmacology & Therapeutics · 被引 9)
• Radiomics‐Based Assessment of Portal Hypertension Severity and Risk Stratification of Cirrhotic Patients Using Routine CT Scans (2026 · Liver International · 被引 3)
• Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study (2025 · JHEP Reports · 被引 2)
• Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab (2025 · Journal for ImmunoTherapy of Cancer · 被引 2)
• Non‐Invasive Stratification of Portal Hypertension in Patients With BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms (2025 · Liver International · 被引 1)